By: 11 January 2023
Companion Spine acquires Backbone SAS, expanding its portfolio of medical implants dedicated to treating spine and back pain

Companion Spine LLC, the French-American specialist in diagnostic and interventional spine pain-management surgery, recently announced the acquisition of Backbone SAS, a company based in Bordeaux, France, that designs, develops, manufactures and markets functional motion restoration implantable devices to treat spinal disorders.

The acquisition expands Companion Spine’s portfolio of medical implant solutions with the inclusion of Backbone’s main medical device, the LISA® implant (a Lumbar Implant for Stiffness Augmentation).
This acquisition allows Companion Spine to complete its line of treatment solutions for spine diseases, most notably lumbar stenosis and degenerative disc disease, matching implants to the degree of severity of the disease.
Degenerative spine diseases are one of the leading causes of disability in the world, with nearly 403 million cases of symptomatic disc degeneration, more than 5% of the world’s population, and 103 million cases of spinal stenosis per year worldwide. [1]
Founded in 2020 by the American investment company Viscogliosi Brothers, LLC, which specializes in financing disruptive therapeutic innovations in spine, orthopedic and other healthcare indications, Companion Spine is a specialist in back pain management, motion preservation, precision diagnostics and interventional care that enables comprehensive management of spine diseases. Companion Spine’s solutions provide patients and the medical community with a continuum of care for better management of spine conditions.
The LISA® implant, the main medical device from Backbone, is an effective solution that meets the growing need to treat progressive spinal pathologies more effectively. The device reduces chronic pain related to degenerative diseases of the lumbar spine, preserving form, function and motion, while balancing and restoring the patient’s freedom of movement.
The LISA® implant has been CE marked since 2018. Backbone conducted a clinical study on 137 patients in 5 centers in Europe to demonstrate its safety and eff